MOLOGNI LUCA
- U08, Piano: 4, Stanza: LABORATORIO 4.10
- U08, Piano: 4, Stanza: 4043
Pubblicazioni
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio
Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio
Introvigne, M., Destro, L., Mologni, L., Crippa, V., Zardi, P., Fini, F., et al. (2025). α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML. CHEMMEDCHEM, 20(1) [10.1002/cmdc.202400622]. Dettaglio
Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Dettaglio
Villa, M., Cazzaniga, G., Bolognesi, M., Malighetti, F., Crippa, V., Aroldi, A., et al. (2025). Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers. HELIYON, 11(12 (July 2025)) [10.1016/j.heliyon.2025.e43533]. Dettaglio